undamentalytics Newsletter
Sign in

Brainsway Ltd. (BWAY) stock

Add to watchlist

Add holding +

NASDAQ: BWAY Nasdaq Health Care Equipment Next results ~November 10, 2026

Brainsway Ltd. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Brainsway Ltd. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 3 selling0 purchases and 7 sales by directors and officers, last 12 monthsInsider trades
  • Funds22 adding, 27 cuttingOf 12 active managers that changed their stake, 2 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Brainsway files

Where Brainsway stands after its latest Filing

Revenue for the twelve months was $52m, up 27.3% on a year earlier, slower than the 29.0% growth a quarter earlier. Free-cash-flow margin rose to 33.0% from -4.6% a year earlier. Operating margin widened to 8.3% from -16.9%. The diluted share count is up 11.9% on a year earlier, which dilutes existing holders. It passes 2 of our 2 financial-health checks.

Our model value for Brainsway is under review, so past values are not shown until it is resolved.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 10, 2026 (estimated)

Brainsway Ltd.'s trailing-twelve-month revenue grew 27.3% year on year, with a free-cash-flow margin of 33.0%.

Our discounted-cash-flow model values the business at ~$14 per share in the base case (~$11–$18 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 70.5% while net income grew 159.3%: a 89pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 27.3% over the last 12 months.
  • Margins widening. Operating margin is up 4.9 points on a year ago.
  • Strong cash generation. 33.0% of revenue turned into free cash flow.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Share dilution. Diluted shares rose 11.9% in a year.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results

Earnings per share
$0.07 against an average estimate of $0.07: missed by 4.5%
Next report
November 10, 2026; average EPS estimate $0.09

Brainsway's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.4%
  • 1 week-1.1%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$52.2M
Operating margin
8.3%
Net margin
14.5%
EPS (TTM, diluted)
$0.20

Growth

Revenue growth
+27.3%
Change in growth rate
−1.7 pts
Share count change
+11.9%

Cash

Free cash flow (TTM)
$17.2M
FCF margin
33.0%
Stock pay % of revenue
2.3%

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for BWAY from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Brainsway Ltd. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Brainsway Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. — Does not apply: This model is withheld pending its input or assumption review.
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$8.3 ~$7.3–$13 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Brainsway Ltd. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 10, 2026, before the open. Analysts expect revenue of $18m and EPS of $0.09 (range $0.07 to $0.12) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.31 +70% $69m +32%
Next $0.51 +65% $85m +23%

Next year's EPS estimate has moved +4.8% in 90 days, across 3 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is 0.0% on 90 days ago. In the last 30 days, 2 analysts raised Brainsway Ltd.'s forecast and 1 cut it.

Consensus EPS forecast Brainsway Ltd., last 90 days
$0.20 $0.30 $0.40 $0.50 $0.60 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.31 Current fiscal year, 60 days ago: $0.27 Current fiscal year, 30 days ago: $0.31 Current fiscal year, 7 days ago: $0.31 Current fiscal year, Now: $0.31 $0.31 Next fiscal year, 90 days ago: $0.48 Next fiscal year, 60 days ago: $0.49 Next fiscal year, 30 days ago: $0.51 Next fiscal year, 7 days ago: $0.51 Next fiscal year, Now: $0.51 $0.51

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.31$0.48
60 days ago $0.27$0.49
30 days ago $0.31$0.51
7 days ago $0.31$0.51
Now $0.31$0.51

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.07 $0.07 −4.5%
Mar 2026 $0.05 $0.06 +20.0%
Dec 2025 $0.03 $0.06 +155.4%
Sept 2025 $0.02 $0.02 −14.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

3 analysts, Nov 2026
Buy3100%
Hold00%
Sell00%

Monthly trend

  1. Nov 202633
  2. Oct 202633
  3. Sep 202633

Counts of recommendations published by analysts covering Brainsway Ltd., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
0.7%
of tradable shares
Days to cover
2.02
at average volume
Short interest, 1 month
+13%
to October 15, 2026
Held by institutions
29%
of shares
Held by insiders
6.1%
of shares
Employees
129
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Revenue (TTM) Brainsway Ltd.
$0 $20M $40M $60M FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Revenue (TTM), FY17 Q4: $11.1M Revenue (TTM), FY18 Q4: $16.4M Revenue (TTM), FY19 Q4: $23.1M Revenue (TTM), FY20 Q4: $22.1M Revenue (TTM), FY21 Q4: $29.7M Revenue (TTM), FY22 Q4: $27.2M Revenue (TTM), FY23 Q4: $31.8M Revenue (TTM), FY24 Q4: $41M Revenue (TTM), FY25 Q4: $52.2M $52.2M

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period Revenue (TTM)
FY17 Q4 $11.1M
FY18 Q4 $16.4M
FY19 Q4 $23.1M
FY20 Q4 $22.1M
FY21 Q4 $29.7M
FY22 Q4 $27.2M
FY23 Q4 $31.8M
FY24 Q4 $41M
FY25 Q4 $52.2M
Revenue growth, TTM YoY Brainsway Ltd.
-20% 0% 20% 40% 60% FY18 Q4 FY20 Q4 FY22 Q4 FY25 Q4 Revenue growth, TTM YoY, FY18 Q4: 47.1% Revenue growth, TTM YoY, FY19 Q4: 40.9% Revenue growth, TTM YoY, FY20 Q4: -4.5% Revenue growth, TTM YoY, FY21 Q4: 34.5% Revenue growth, TTM YoY, FY22 Q4: -8.4% Revenue growth, TTM YoY, FY23 Q4: 17.0% Revenue growth, TTM YoY, FY24 Q4: 29.0% Revenue growth, TTM YoY, FY25 Q4: 27.3% 27.3%

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period Revenue growth, TTM YoY
FY18 Q4 47.1%
FY19 Q4 40.9%
FY20 Q4 -4.5%
FY21 Q4 34.5%
FY22 Q4 -8.4%
FY23 Q4 17.0%
FY24 Q4 29.0%
FY25 Q4 27.3%
Operating margin (TTM) Brainsway Ltd.
-60% -40% -20% 0% 20% FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Operating margin (TTM), FY17 Q4: -59.3% Operating margin (TTM), FY18 Q4: -31.2% Operating margin (TTM), FY19 Q4: -36.7% Operating margin (TTM), FY20 Q4: -21.9% Operating margin (TTM), FY21 Q4: -16.9% Operating margin (TTM), FY22 Q4: -46.7% Operating margin (TTM), FY23 Q4: -15.6% Operating margin (TTM), FY24 Q4: 3.4% Operating margin (TTM), FY25 Q4: 8.3% 8.3%

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period Operating margin (TTM)
FY17 Q4 -59.3%
FY18 Q4 -31.2%
FY19 Q4 -36.7%
FY20 Q4 -21.9%
FY21 Q4 -16.9%
FY22 Q4 -46.7%
FY23 Q4 -15.6%
FY24 Q4 3.4%
FY25 Q4 8.3%
FCF margin (TTM) Brainsway Ltd.
-60% -40% -20% 0% 20% 40% FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 FCF margin (TTM), FY17 Q4: -39.9% FCF margin (TTM), FY18 Q4: -35.0% FCF margin (TTM), FY19 Q4: -45.7% FCF margin (TTM), FY20 Q4: -17.7% FCF margin (TTM), FY21 Q4: -4.6% FCF margin (TTM), FY22 Q4: -36.3% FCF margin (TTM), FY23 Q4: 3.7% FCF margin (TTM), FY24 Q4: 24.6% FCF margin (TTM), FY25 Q4: 33.0% 33.0%

Source: SEC EDGAR filings. Retrieved November 2, 2026.

View chart data
Period FCF margin (TTM)
FY17 Q4 -39.9%
FY18 Q4 -35.0%
FY19 Q4 -45.7%
FY20 Q4 -17.7%
FY21 Q4 -4.6%
FY22 Q4 -36.3%
FY23 Q4 3.7%
FY24 Q4 24.6%
FY25 Q4 33.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Brainsway took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $52.2M
  2. Other income $3.4M · 6.5%
  3. Cost of revenue $12.8M · 24.6%
  4. Gross profit $39.4M · 75.4%
  5. Research and development $9.6M · 18.4%
  6. Other operating costs $25.5M · 48.8%
  7. Operating income $4.3M · 8.3%
  8. Net income $7.6M · 14.5%

Shares of revenue. Source: Brainsway's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained. Other income is income outside operations, such as investment gains.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 11 16 23 22 30 27 32 41 52
Gross profit 9 13 18 17 23 20 23 31 39
EBITDA −7 −5 −8 −5 −5 −13 −5 2 5
Operating income −7 −5 −8 −5 −5 −13 −5 1 4
Net income −7 −6 −10 −5 −6 −13 −4 3 8
Diluted EPS — — — — −$0.21 −$0.40 −$0.13 $0.05 $0.18
Growth (year on year)
Revenue — +47.1% +40.9% −4.5% +34.5% −8.4% +17.0% +29.0% +27.3%
EBITDA — — — — — — — — +188.8%
Operating income — — — — — — — — +210.8%
Net income — — — — — — — — +159.3%
Diluted EPS — — — — — — — — +260.0%
Margins
Gross margin 76.7% 78.1% 77.8% 77.1% 77.7% 73.8% 73.9% 74.6% 75.4%
EBITDA margin −59.0% −31.0% −36.5% −21.5% −16.5% −46.3% −15.3% 3.9% 8.8%
Operating margin −59.3% −31.2% −36.7% −21.9% −16.9% −46.7% −15.6% 3.4% 8.3%
Net margin −63.3% −39.5% −44.7% −24.4% −21.8% −49.1% −13.2% 7.1% 14.5%
Free-cash-flow margin −39.9% −35.0% −45.7% −17.7% −4.6% −35.9% 4.0% 25.1% 33.5%
Cash flow
Cash from operations −3 −4 −7 −1 1 −10 1 10 17
Capital spending 1 2 3 2 2 0 0 0 0
Free cash flow −4 −6 −11 −4 −1 −10 1 10 17
Stock-based pay 1 1 1 1 2 1 0 1 1
Free cash flow after stock pay −5 −6 −12 −5 −3 −11 1 9 16
Balance sheet
Cash 15 9 22 17 17 48 11 69 68
Total debt 0 3 — 0 0 0 0 0 0
Net debt (negative = net cash) −15 −6 −22 −17 −17 −48 −11 −69 −68
Diluted shares 15m 17m 21m 22m 31m 33m 33m 34m 38m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · December 31, 2025
What it owns · $113m
Short-term assets $84mLonger-term assets $29m
What it owes, and who funded it · $96m
Short-term liabilities $22mShareholders' equity $73m
  • Short-term assets cover short-term liabilities $84m of assets due within a year against $22m of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of $4m against $581,000 of interest.

From Brainsway Ltd.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+11.9%
year over year
R&D spending
18.4%
of revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated BWAY IRIX SENS APYX CLPT LNSR Median
Revenue, last 12 months $52m $52m $49m $58m $45m $60m $95m
Revenue growth, last 12 months 27.3% 3.7% 90.6% 25.6% 32.5% 3.3% 9.3%
Revenue growth, 3-year average — −2.9% 38.0% 7.2% 26.8% 16.4% 13.5%
Revenue growth, latest quarter — −7.4% 117.8% 22.1% 36.3% 18.4% 10.2%
Gross margin 75.4% 35.9% 54.9% 63.5% 61.4% 48.3% 61.3%
Operating margin 8.3% −5.4% −223.2% −6.1% −70.6% −13.5% −8.3%
Operating margin, 3-year average −22.6% −11.3% −261.7% −26.2% −66.2% −22.5% −17.9%
Net margin 14.5% −6.9% −225.3% −14.8% −79.4% 57.6% −11.7%
Cash from operations / revenue 33.5% −3.4% −197.6% −17.3% −103.6% −12.1% −1.7%
Free-cash-flow margin 33.0% −3.9% −199.5% −18.9% −105.9% −12.1% −3.9%
Free-cash-flow margin, 3-year average −3.9% −9.1% −230.3% −20.1% −58.5% −14.5% −6.2%
Stock pay / revenue 2.3% 1.4% 23.2% 4.1% 18.4% 4.6% 6.1%
Change in share count 11.9% 3.3% −2.8% 10.5% 6.7% 33.3% 4.0%

Median of all 135 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$174M
Institutions reporting
55
Shares held vs prior quarter
▼ 2.5%
Positions opened / closed
8 / 8

Top buyers and sellers, Q2 2026: 22 institutions bought and 27 sold ; the biggest buyer was Morgan Stanley (+85K shares) and the biggest seller Masters Capital Management LLC (−150K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Valor Management LLC $82.4M 5.3M 47.3% 0.0%
Masters Capital Management LLC $23.3M 1.5M 13.4% ▼ 9.1%
Acadian Asset Management LLC $12.5M 808K 7.2% ▼ 1.3%
Essex Investment Management Co LLC $9.2M 593K 5.3% ▼ 4.2%
Renaissance Technologies LLC $7.4M 476K 4.2% ▼ 8.2%
Cresset Asset Management, LLC $4.9M 315K 2.8% 0.0%
Y.D. More Investments Ltd $3.7M 237K 2.1% ▼ 12.7%
Morgan Stanley $2.9M 189K 1.7% ▲ 81.0%
Eagle Global Advisors LLC $2.8M 183K 1.6% ▲ 5.8%
ARK Investment Management LLC $2.2M 143K 1.3% ▼ 26.4%
Sei Investments Co $1.9M 120K 1.1% ▼ 47.1%
UBS Group AG $1.6M 101K 0.9% ▲ 23.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Brainsway Ltd.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 7 trades by 3 insiders · 0% under pre-set plans
Net ▲ $0 net buying
Insider Date Trade Shares Price Value
Moiseyev Gilad Chief Technology Officer June 15, 2026 Sell 5,000 — $0
Roth Yiftach Chief Scientist June 2, 2026 Sell 1,000 — $0
Roth Yiftach Chief Scientist June 2, 2026 Sell 2,000 — $0
Roth Yiftach Chief Scientist June 1, 2026 Sell 2,000 — $0
Roth Yiftach Chief Scientist June 1, 2026 Sell 2,000 — $0
Mitrany Rayten Michal Ety Director May 26, 2026 Sell 7,980 — $0
Mitrany Rayten Michal Ety Director May 25, 2026 Sell 10,000 — $0

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Brainsway Ltd. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Brainsway Ltd. in brief

What does Brainsway Ltd. do?
Brainsway Ltd. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Brainsway Ltd.'s stock ticker?
Brainsway Ltd. trades under the ticker BWAY on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Brainsway Ltd.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Brainsway Ltd. reported revenue of $52.2M, 27.3% higher than a year earlier, according to its SEC filings.
What is Brainsway Ltd.'s free cash flow?
Brainsway Ltd.'s free-cash-flow margin is 33.0% of revenue over the trailing twelve months.
Who are Brainsway Ltd.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Valor Management LLC, Masters Capital Management LLC and Acadian Asset Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Who are Brainsway Ltd.'s competitors?
In our Health Care Equipment peer group, the companies closest to Brainsway Ltd. are Iridex Corp, Senseonics Holdings, Inc., Apyx Medical Corp, Clearpoint Neuro, Inc. and Lensar, Inc. The side-by-side comparison below sets their revenue, margins and growth against Brainsway Ltd.'s.
Are insiders buying or selling Brainsway Ltd. stock?
Over the last 12 months, Brainsway Ltd.'s directors and officers reported 0 open-market purchases and 7 sales on Form 4. The insider trading page charts every trade.
When is Brainsway Ltd.'s next earnings date?
Around November 10, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Brainsway Ltd. announces its own schedule.